Opportunity summary
Score7.0Public score shown from the verified overall while the stale axis breakdown refreshesThis canonical paper page includes Commercialization Proof and Related Resources.
ARXIV:2603.26510 · MEDICAL AI · SUBMITTED 30 MAR · 20:30 UTC · FRESHNESS STALE
ARXIV:2603.26510MEDICAL AISUBMITTED 30 MAR · 20:30 UTCFRESHNESS STALEVinicius Anjos de Almeida · Sandro Saorin da Silva · Josimar Chire · Leonardo Vicenzi · Nícolas Henrique Borges · Helena Kociolek · +5 at arXiv
A benchmark of modern BERT and LLMs for clinical named entity recognition in Portuguese, demonstrating strong performance with mmBERT and balanced data strategies.
Opportunity summary
Pain A benchmark of modern BERT and LLMs for clinical named entity recognition in Portuguese, demonstrating strong performance with mmBERT and balanced data strategies.
Evidence 12 refs | 5 sources | 83% coverage
Blocker Evidence verified
A benchmark of modern BERT and LLMs for clinical named entity recognition in Portuguese, demonstrating strong performance with mmBERT and balanced data strategies. Named entity recognition (NER) enables the automatic extraction of medical concepts;…
Clinical notes contain valuable unstructured information. Named entity recognition (NER) enables the automatic extraction of medical concepts; however, benchmarks for Portuguese remain scarce.
ScienceToStartup currently rates this 7.0/10 on the public viability pass. Named entity recognition (NER) enables the automatic extraction of medical concepts; however, benchmarks for Portuguese remain scarce. A public repository is linked, so build…
Medical AI moved forward this cycle; last verified April 2026. Public score 7.0/10. Implementation evidence is present through a linked repository.
Continue into Read for claims, analysis, references, and neighboring papers.
mobile layout uses overflow-hidden min-w-0 break-wordsOpportunity summary
Score7.0Public score shown from the verified overall while the stale axis breakdown refreshesAnalysis summary
A benchmark of modern BERT and LLMs for clinical named entity recognition in Portuguese, demonstrating strong performance with mmBERT and balanced data strategies.
Loading BUILD…
Paper Pack
10.48550/arXiv.2603.26510A benchmark of modern BERT and LLMs for clinical named entity recognition in Portuguese, demonstrating strong performance with mmBERT and balanced data strategies.
Abstract
Clinical notes contain valuable unstructured information. Named entity recognition (NER) enables the automatic extraction of medical concepts; however, benchmarks for Portuguese remain scarce. In this study, we aimed to evaluate BERT-based models and large language models (LLMs) for clinical NER in Portuguese and to test strategies for addressing multilabel imbalance. We compared BioBERTpt, BERTimbau, ModernBERT, and mmBERT with LLMs such as GPT-5 and Gemini-2.5, using the public SemClinBr corpus and a private breast cancer dataset. Models were trained under identical conditions and evaluated using precision, recall, and F1-score. Iterative stratification, weighted loss, and oversampling were explored to mitigate class imbalance. The mmBERT-base model achieved the best performance (micro F1 = 0.76), outperforming all other models. Iterative stratification improved class balance and overall performance. Multilingual BERT models, particularly mmBERT, perform strongly for Portuguese clinical NER and can run locally with limited computational resources. Balanced data-splitting strategies further enhance performance.
Source availability
PDF linkedThe paper record includes a public PDF URL.
Extraction status
Parse run linkedA document parse run is attached to this paper.
Proof status
verified12 refs; 5 sources; 83% coverage.
What was readable
Derived fallback: Estimated from adjacent evidence; not verified from source.
Viability
Time to MVP
Commercial
Export
Dimensions overall score 7.0
PROBLEM
A benchmark of modern BERT and LLMs for clinical named entity recognition in Portuguese, demonstrating strong performance with mmBERT and balanced data strategies. Named entity recognition (NER) enables the automatic extraction of medical concepts; however, benchmarks for Portug...
METHOD
Clinical notes contain valuable unstructured information. Named entity recognition (NER) enables the automatic extraction of medical concepts; however, benchmarks for Portuguese remain scarce.
RESULT
ScienceToStartup currently rates this 7.0/10 on the public viability pass. Named entity recognition (NER) enables the automatic extraction of medical concepts; however, benchmarks for Portuguese remain scarce. A public repository is linked, so build verification can inspect impl...
WHY NOW
Medical AI moved forward this cycle; last verified April 2026. Public score 7.0/10. Implementation evidence is present through a linked repository.
The mmBERT-base model achieved the best performance (micro F1 = 0.76), outperforming all other models.
This is a direct result stated in the abstract and confirmed in the results section with a specific F1 score.
verified
Iterative stratification improved class balance and overall performance.
The abstract explicitly states this as a finding, and the results section implies its positive impact.
partial
Multilingual BERT models, particularly mmBERT, perform strongly for Portuguese clinical NER and can run locally with limited computational resources.
This claim is directly stated in the abstract and supported by the results showing mmBERT's superior performance and the technical advantage of local execution.
partial
BERT models, in general, have demonstrated better performance when compared to leading LLMs in the industry.
The results section states this comparison, highlighting BERT's advantage over LLMs in this specific task.
partial
We compared BioBERTpt, BERTimbau, ModernBERT, and mmBERT with LLMs such as GPT-5 and Gemini-2.5
This is a direct statement of the models included in the comparison, found in both the abstract and methods section.
partial
mmBERT-base established a new state-of-the-art on the SemClinBr dataset (micro F1-score = 0.7646).
This is a specific and verifiable result with a precise F1 score, directly stated in the results section.
partial
The experiments involving increased reasoning effort using the gpt-5 model demonstrate a modest gain in performance that was not able to surpass every BERT model.
The results section discusses the impact of increased reasoning effort on LLMs, noting the limited performance improvement.
partial
The mmBERT-base model achieved the best performance (micro F1 = 0.76), outperforming all other models.
The abstract and results section explicitly state this finding and provide the specific F1-score.
verified
Iterative stratification improved class balance and overall performance.
The abstract and results section mention the exploration and positive impact of iterative stratification.
partial
Multilingual BERT models, particularly mmBERT, perform strongly for Portuguese clinical NER and can run locally with limited computational resources.
This is a direct conclusion stated in the abstract, highlighting both performance and technical feasibility.
partial
BERT models, in general, have demonstrated better performance when compared to leading LLMs in the industry. They also had faster inference and ran locally on domestic hardware, enabling experiments with no privacy risks.
The results section directly compares BERT models to LLMs and highlights these advantages.
partial
We compared BioBERTpt, BERTimbau, ModernBERT, and mmBERT with LLMs such as GPT-5 and Gemini-2.5, using the public SemClinBr corpus and a private breast-cancer dataset.
This is a direct statement of the models compared in the abstract and methods section.
partial
Paper-native neighborhood for concepts, methods, materials, markets, and competitors. Missing lanes stay labeled instead of disappearing behind commercialization gates.
Concepts
Methods
Materials
Markets
Competitors
A benchmark of modern BERT and LLMs for clinical named entity recognition in Portuguese, demonstrating strong performance with mmBERT and balanced data strategies.
Segment
Medical AI
Adoption evidence
Public code linked for build inspection
Commercial read
7.0/10 public viability
Direct
Adjacent
Substitute
Unknown
No indexed public discussion is attached to 2603.26510 yet. That is a visibility signal, not a blank module: the monitor is watching the public channels below.
Hacker News
Not indexed yet
Not indexed yet
Bluesky
Not indexed yet
Preview the source document here, or use the hero PDF action for a new tab.
Reference metadata is not materialized in the public index yet. The source PDF remains the authority; cache refresh is optional.
CITED BY
No citing papers are indexed in the public S2S graph yet. This is an explicit zero-signal state, not a hidden lookup.
Foundation
Extension
Commercially relevant
Owned Distribution
Get the weekly shortlist of commercializable papers, benchmark movers, and proof receipts that matter for product execution.
Build Passport
Build passport pending - Proof Lab budget No verified cost estimate / $7.00 cap
status
missing
reason
passport_row_missing
proof status
unverified
cost/budget
No verified cost estimate
confidence low
next verification path
Build brief missing until Build Passport data exists.
Source missing: Build Passport payload.
Experiment plan missing until prototype path is available.
No prototype path attached.
Validation checklist missing until required assets, cost, and regulatory flags are verified.
No checklist artifact is attached to the Build Passport payload.
Derived signals show verified:false until source-backed receipts exist.
Evidence coverage
OpportunityKernel evidence_receipt
12 refs / 5 sources / 83% coverage
stale
Verify missing sources before using this as buyer proof. verified:false
Build readiness
BuildPassport EvidenceState
passport absent
stale
Run Proof Lab or inspect typed missing state. verified:false
Artifact maturity
GitHub and Hugging Face maturity payloads
No public artifact surface observed
stale
Open source artifacts or mark the gap as missing. verified:false
Technical feasibility
partial
Current read
Runnable path is not fully verified.
Evidence
No Build Passport payload attached.
Gaps
Next test
Run minimal reproduction from the Build Passport prototype path.
Market urgency
partial
Current read
Research evidence exists; buyer urgency still needs source proof.
Evidence
12 references, 5 sources, 83% evidence coverage.
Gaps
Next test
Collect buyer interview, deployment evidence, or cited demand signal.
Buyer clarity
missing
Current read
No budget owner is verified for this paper.
Evidence
Build tab has no CRM, procurement, or operator source.
Gaps
Next test
Map target operator, economic buyer, and procurement trigger.
Defensibility
missing
Current read
Defensibility signals are missing.
Evidence
No defensibility receipt attached.
Gaps
Next test
Refresh defensibility bars with source receipts.
Integration burden
missing
Current read
No public implementation surface observed.
Evidence
No GitHub or Hugging Face payload attached.
Gaps
Next test
Write integration checklist from prototype path and target workflow.
Capital intensity
missing
Current read
No observed cost estimate is verified.
Evidence
Cost passport has no observed_usd value.
Gaps
Next test
Run cost passport or mark the cost field not applicable.
Regulatory load
missing
Current read
No regulatory classification is attached.
Evidence
Build Passport ledger does not include regulatory flags.
Gaps
Next test
Classify regulatory flags before commercialization planning.
No named scientific founder assigned.
Paper authors are not treated as operators without consent.
People
No named person assigned.
Gaps
Next verification path
Prototype owner missing.
Build Passport does not name an implementer.
People
No named person assigned.
Gaps
Next verification path
Operator workflow not sourced.
No buyer or workflow interview attached.
People
No named person assigned.
Gaps
Next verification path
No GTM owner verified.
No CRM or outreach source attached.
People
No named person assigned.
Gaps
Next verification path
Regulatory need unclassified.
No clinical or regulatory source attached.
People
No named person assigned.
Gaps
Next verification path
ARTIFACTS
No public artifacts yet.
DEFENSIBILITY
Defensibility and confidence evidence pending.
Use an AI coding agent to implement this research.
Lightweight coding agent in your terminal.
Agentic coding tool for terminal workflows.
AI agent mindset installer and workflow scaffolder.
AI-first code editor built on VS Code.
Free, open-source editor by Microsoft.
Estimated $9K - $13K over 6-10 weeks.
See exactly what it costs to build this -- with 3 comparable funded startups.
7-day free trial. Cancel anytime.
Discover the researchers behind this paper and find similar experts.
7-day free trial. Cancel anytime.
Understand the commercial significance and market impact.
7-day free trial. Cancel anytime.
Get detailed profiles of the research team.
7-day free trial. Cancel anytime.
WATCHTOWER
No verified watchtower monitor rows yet.
FORESIGHT
No prediction yet — minted on next Foresight batch.
OPPORTUNITYKERNEL CHANGES SINCE LAST VIEW
No verified OpportunityKernel changes since the last view.
COMPETITIVE LANDSCAPE UPDATES
No verified competitive landscape changes yet.
RELATED PAPER UPDATES
No verified related paper changes yet.
SIGNAL CANVAS HISTORY AND DELTAS
No Signal Canvas history deltas yet.
TIMELINE
Save this paper to start tracking momentum - commits, demos, and score changes appear here.
No tracked events yet.
Score trend will appear after multiple data points.
BUZZ
Buzz trend pending.